NCT05730725CompletedPhase 2
A Study to Evaluate Effectiveness and Safety of BMS-986322 in Participants With Moderate-to-Severe Psoriasis
A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Phase 2 Study to Evaluate the Clinical Efficacy and Safety of BMS-986322 in Participants With Moderate-to-Severe Psoriasis
Source: ClinicalTrials.gov · Last updated 25 Nov 2025
Brief summary (registry, in English)
The purpose of this study is to evaluate clinical effectiveness and safety of BMS-986322 in participants with moderate-to-severe psoriasis.
- Status (registry)
- Completed
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 109 (actual)
- First submitted
- 7 Feb 2023
- Start date
- 3 Apr 2023
- Primary completion date
- 6 Aug 2024
- Lead sponsor
- Bristol-Myers Squibb
- Diseases
- Psoriasis
- NCT number
- NCT05730725
- EudraCT number
- 2023-504848-34
What you commit to
- Study type: Interventional · Phase 2
- Participants enrolled: 109
- From 3 Apr 2023 to the primary completion date, 6 Aug 2024
- 35 sites in 5 countries
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Diagnosis of uveitis, inflammatory bowel disease, or other immune-mediated conditions that are commonly associated with PsO for which a participant requires current systemic immunosuppressant medical treatment
- Any significant acute or chronic medical illness
- Other protocol-defined inclusion/exclusion criteria apply
Other
- Diagnosis of non-plaque psoriasis (guttate, inverse, pustular, erythrodermic)
Who the study is looking for
- Diagnosis of plaque psoriasis (PsO) for ≥ 6 months
- Body mass index 18 to 40 kg/m\^2 and total body weight \> 50 kg (110 lbs)
- Deemed by Investigator to be eligible for phototherapy or systemic therapy
- Psoriatic plaques must cover ≥ 10% of body surface area at baseline
- Psoriasis Area and Severity Index (PASI) score ≥ 12 and static Physician Global Assessment (sPGA) ≥ 3 at baseline
Age in the registry: 18 years to 70 years · Sex: All · Does not accept healthy volunteers
Sites (35)
Sites in registry order. Pick your city on the disease page to sort them by distance.
This page is information, not medical advice. Discuss any trial with your doctor.